Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 6/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14738063 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2DPP4DPP8DPP9DPP7 | |
| SCHEMBL4314187 | 0.91 | L3MBTL1 (0.34) | DPP4DPP8DPP9DPP7GRM2 | |
| SCHEMBL4327147 | 0.89 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL4333641 | 0.86 | DPP4 (0.30) | DPP4 | |
| SCHEMBL29659494 | 0.82 | FGFR2 (0.34) | SMN1; SMN2DPP4DPP8DPP9DPP7 | |
| SCHEMBL29659607 | 0.82 | FGFR2 (0.34) | SMN1; SMN2DPP4DPP8DPP9DPP7 | |
| SCHEMBL29659728 | 0.82 | FGFR2 (0.34) | SMN1; SMN2DPP4DPP8DPP9DPP7 | |
| SCHEMBL4320581 | 0.81 | PDCD1 (0.35) | SMN1; SMN2DPP4DPP7 | |
| SCHEMBL4316264 | 0.78 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL4327227 | 0.77 | SMN1; SMN2 (0.37) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | claimed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | claimed |
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK1 | SMN1; SMN2 4803/4885DPP4 1636/4885DPP8 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.